Galapagos NV

LSE:0JXZ Stock Report

Market Cap: €1.7b

Galapagos Valuation

Is 0JXZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JXZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0JXZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0JXZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JXZ?

Key metric: As 0JXZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0JXZ. This is calculated by dividing 0JXZ's market cap by their current revenue.
What is 0JXZ's PS Ratio?
PS Ratio6.6x
Sales€260.09m
Market Cap€1.72b

Price to Sales Ratio vs Peers

How does 0JXZ's PS Ratio compare to its peers?

The above table shows the PS ratio for 0JXZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
GNS Genus
1.7x3.5%UK£1.1b
OXB Oxford Biomedica
4.6x21.0%UK£447.3m
BVXP Bioventix
14.4xn/aUK£195.7m
AVCT Avacta Group
8.1x0.4%UK£182.9m
0JXZ Galapagos
6.6x3.9%€1.7b

Price-To-Sales vs Peers: 0JXZ is good value based on its Price-To-Sales Ratio (6.6x) compared to the peer average (7.2x).

Price to Sales Ratio vs Industry

How does 0JXZ's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.39b
OXB Oxford Biomedica
4.6x21.0%US$561.36m
TRX Tissue Regenix Group
1.6x15.1%US$50.96m
VRCI Verici Dx
2.4x78.8%US$10.27m
0JXZ 6.6xIndustry Avg. 8.1xNo. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0JXZ is good value based on its Price-To-Sales Ratio (6.6x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 0JXZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JXZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.6x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: 0JXZ is expensive based on its Price-To-Sales Ratio (6.6x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JXZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€26.14
€35.37
+35.3%
21.5%€50.00€28.00n/a9
Nov ’25€24.39
€35.59
+45.9%
21.0%€50.00€28.00n/a9
Oct ’25€26.13
€36.03
+37.9%
18.3%€50.00€30.00n/a10
Sep ’25€26.55
€36.03
+35.7%
18.3%€50.00€30.00n/a10
Aug ’25€24.86
€36.73
+47.7%
16.9%€50.00€30.00n/a10
Jul ’25€23.38
€36.73
+57.1%
16.9%€50.00€30.00n/a10
Jun ’25€25.74
€36.73
+42.7%
16.9%€50.00€30.00n/a10
May ’25€26.66
€38.43
+44.1%
15.7%€50.00€30.00n/a10
Apr ’25€29.77
€39.43
+32.5%
16.7%€55.00€33.00n/a10
Mar ’25€32.36
€39.53
+22.2%
16.6%€55.00€33.00n/a10
Feb ’25€34.55
€39.94
+15.6%
14.9%€55.00€34.00n/a11
Jan ’25€37.09
€39.85
+7.4%
14.8%€55.00€34.00n/a11
Dec ’24€34.53
€40.57
+17.5%
13.8%€55.00€35.00n/a11
Nov ’24€31.21
€41.12
+31.7%
12.9%€55.00€35.00€24.3911
Oct ’24€32.66
€41.12
+25.9%
12.9%€55.00€35.00€26.1311
Sep ’24€35.17
€41.03
+16.7%
13.0%€55.00€35.00€26.5510
Aug ’24€38.90
€41.72
+7.2%
15.3%€55.00€35.00€24.869
Jul ’24€37.42
€40.06
+7.1%
11.5%€51.00€35.00€23.388
Jun ’24€38.39
€40.06
+4.4%
11.5%€51.00€35.00€25.748
May ’24€35.11
€41.78
+19.0%
15.2%€51.00€35.00€26.666
Apr ’24€34.89
€45.94
+31.7%
25.4%€67.00€35.00€29.775
Mar ’24€35.12
€46.78
+33.2%
21.7%€67.00€35.00€32.366
Feb ’24€40.20
€51.78
+28.8%
20.2%€67.00€40.00€34.556
Jan ’24€41.41
€52.86
+27.7%
17.7%€67.00€40.00€37.097
Dec ’23€38.11
€55.00
+44.3%
18.4%€67.00€40.00€34.537
Nov ’23€46.77
€57.14
+22.2%
13.4%€67.00€48.00€31.217

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

7D

-2.1%

1Y

-6.5%